Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODE study of CER-001 in homozygous familial hypercholesterolemia
2011-003998-28Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CER-001 in homozygous familial hypercholesterolemia (HoFH), sponsored by ABIONYX Pharma. Primary endpoint: Percent change from baseline in carotid plaque volume. Started Oct 2011; status: completed.
02
Drugs
CER-001
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2011-003998-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003998-28.